AntiCancer Announces It Has Rejuvenated Aged Hair Follicles

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. has demonstrated that aged mouse hair follicles are rejuvenated after transplantation to young mice. Young mice promote the hair shaft growth from transplanted old hair follicles, in contrast to old host mice, which did not support hair-shaft growth from transplanted old hair follicles. The young mice appear to rejuvenate the stem cells of the follicles of the old transplanted hair follicles. This new study is published in Cell Cycle (http://www.tandfonline.com/doi/full/10.1080/15384101.2016.1156269).

“These results indicate hair aging is reversible and possibly all aging may be reversible”

“These results indicate hair aging is reversible and possibly all aging may be reversible,” said Charlene Cooper, Vice President and Chief Operating Officer of AntiCancer Inc. “AntiCancer scientists are working on the mechanism by which hair follicles are rejuvenated.”

AntiCancer Inc., founded in 1984 and based in San Diego, with offices and laboratories in Seoul, Beijing, Nanjing and Tokyo, has developed the leading mouse models of cancer including MetaMouse^®, AngioMouse^® and StromaMouse^®. These mouse models are made imageable with AntiCancer’s OncoBrite^® technology and are the models of choice for novel drug discovery for cancer. With its proprietary mouse models, AntiCancer is the foremost pre-clinical cancer contract research organization. The proprietary mouse models are also available via licensing. AntiCancer offers the world’s largest collection of fluorescent-protein-expressing cancer cell lines and transgenic fluorescent nude mice which are made available commercially. AntiCancer is a pioneer in fluorescence-guided surgery of cancer using its patient-like mouse models. AntiCancer is also developing biological drugs that target cancer-specific metabolic defects, including recombinant methioninase (rMETase). AntiCancer developed the Histoculture Drug Response Assay (HDRA) and patient-derived orthotopic xenografts (PDOX^TM) for individualized cancer treatment which are available in its PDOX LLC subsidiary. AntiCancer is also developing tumor-targeting bacteria for the general cure of cancer. The company markets recombinant-enzyme-based diagnostics for cancer and cardiovascular disease in its wholly-owned A/C Diagnostics LLC subsidiary. AntiCancer has also discovered and developed hair follicle-associated-pluripotent (HAP) stem cells that can differentiate to beating hear cells and other cell types and have been used to repair injured peripheral nerves and spinal cords and also being developed for heart regeneration in its A/C Stem LLC subsidiary.